A U.S. federal appeals court said a judge ‌erred in dismissing a $6.7 billion lawsuit accusing Bristol Myers Squibb of cheating former Celgene shareholders by delaying federal approval for three drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results